{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"14"}],"units":"Participants"}],"description":"The number of participants receiving prophylactic anakinra with no CRS occurring on study days 1, 2, or 3. CRS grade is defined by the most severe symptom (excluding fever). Grade 2=moderate; Grade 3=severe; Grade 4=life-threatening","groups":[{"description":"2 doses of 100 mg anakinra administered subcutaneously (SC) for 5 consecutive days + JCARH125 IV at dose level 600 x 10\\^6 consisting of CD3+CAR+T cells","id":"OG000","title":"Phase 1 Anakinra 600 x 10^6 Cells"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All participants who received at least one infusion of JCARH125 and at least one dose of anakinra as prophylactic intervention in phase 1 Anakinra","reportingStatus":"POSTED","timeFrame":"Day 1, 2, 3","title":"Number of Participants Receiving Prophylactic Anakinra With no Cytokine Release Syndrome (CRS) Occurring on Days 1-3 in Phase 1 Anakinra","type":"PRIMARY","unitOfMeasure":"Participants"}